With the increasing recognition of real-world data opportunities and challenges within the pharmaceutical and biotech industry, life sciences organizations face clear decisions on how specifically to put resources into real-world evidence capacities. Real-World Evidence can possibly change the way life sciences associations use advancements to increase further clinical bits of knowledge and enable them and payers to collaborate like never before. After the successful inaugural, this year’s congress will hold discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation.
District cooling is one of the nine strategic pillars in Dubai Supreme Council of Energy’s Demand Side Management strategy, towards achieving 30% power savings in the emirate by 2030. The major steps for enhancing district cooling adoption includes planning and educating the top players in real estate firms on the advantages and guiding on the knowledge of technical know-how.
This conclave aims to provide a platform to experts from Government bodies, regulatory authorities, real estate firms, special economic zones, hotel owners and operators, free zones from UAE and rest of GCC and solution providers.
What are the essentials being missed out on? What is the real role of probiotics strains, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis?
Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.
Last year, the 4th Edition of this Conference focused on addressing the gaps between early-stage biomarker development and the commercialization stage of biomarkers. Leading industry and academic experts shared their case studies focusing on advancements in the companion diagnostics area. Designed to deliver a forward-looking perspective on the opportunities and challenges impacting market growth for the biomarker industry, the conference will focus on Biomarker Discovery & exploratory Biomarkers and application of biomarkers in Immuno-oncology, neurology and inflammatory diseases.
Since our past editions we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool, gene expression, knock-in, genomic screening, along with therapeutic developments through animal modeling. Attended by 100+ genome editing professionals and 20+ gene expert speakers, the event saw participation of big companies like Casebia Therapeutics, Genentech, BMS, Cellectis , University of Laval, University of California, Center of Advanced Genome Engineering, Georgia Tech, Stanford University, Locana, Harvard Medical School, Agility, Poseida, Vertex, Ligandal, Integrated DNA Technologies, GE Healthcare, Cellecta, Agilent, Advanced Analytical, Thermofisher, Atum, Synthego, New England Biolabs, Aldevron, Applied Stem Cell and more.
Regenerative therapies are proving its acceptance in potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.
In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.
Around 1 in 20 (6%) of patients are affected by preventable harm in medical care, of which around 12% causes permanent disability or death, according to a study published by The BMJ. These infections are contracted by an estimated 1.7 million patients annually and responsible for 99,000 deaths each year.
Preventing disease and controlling spread of resistant bacteria is of major importance when tackling antibiotic resistance. Already, AMR infections are estimated to cause 700,000 deaths each year globally, which is predicted to rise to 10 million, alongside a cumulative cost of $100 trillion, by 2020 if no action is taken.
Where does your success begin? With constant development emerging in global marketing scenario, things have become far more complicated then it seems. Smarter marketing solutions opted by the Chief Marketing professionals give the holistic view over the depth of any industry, economically and ideologically. These solutions help organizations improve their measurement and strategic planning. Smarter the solutions, better the outcomes.